Reference
Soufleris K, et al. Stopping anti-TNFalpha monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapse. Journal of Crohn's and Colitis 12 (Suppl. 1): S391, Feb 2018 [abstract] - Greece
Rights and permissions
About this article
Cite this article
Infliximab. Reactions Weekly 1697, 199 (2018). https://doi.org/10.1007/s40278-018-44755-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-44755-y